# Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

> **NCT00030849** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** bexarotene

## Key facts

- **NCT ID:** NCT00030849
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2004-09
- **Final completion:** 2009-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030849, "Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00030849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*